Regulatory News: <\/p>\n
NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma. <\/p>\n
The clinical trial will be presented during the congress session dedicated to sarcoma. <\/p>\n
This years ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties. <\/p>\n
The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review. <\/p>\n
Laurent Levy, CEO of Nanobiotix said: We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer. <\/p>\n
About NANOBIOTIX - http:\/\/www.nanobiotix.com<\/a> <\/p>\n Nanobiotix (Euronext: NANO \/ ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Companys first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. <\/p>\n Nanobiotixs lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. <\/p>\n Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). <\/p>\n <\/p>\n Read the original post: Regulatory News: NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma. The clinical trial will be presented during the congress session dedicated to sarcoma. This years ASCO will take place in Chicago from 31 May to 3 June, 2014. Continue reading
\nNanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"